SCHEMBL15434011

SCHEMBL15434011

C=CC(=O)Nc1ccccc1Nc1ncc2cc(-c3cc(OC)cc(OC)c3)c(=O)n(C)c2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 16/20 1.00
▸ FGFR2 P21802 3/20 0.64
▸ FGFR1 P11362 5/20 0.58
▸ MAPK3 P27361 1/20 0.54
▸ EGFR P00533 1/20 0.53
▸ FGFR3 P22607 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15434018 0.89 FGFR4 (1.00) FGFR4FGFR2FGFR1EGFRFGFR3
SCHEMBL15434056 0.87 FGFR4 (0.77) FGFR4FGFR2FGFR1MAPK3FGFR3
SCHEMBL16071795 0.86 FGFR4 (1.00) FGFR4FGFR2FGFR1MAPK3EGFR
SCHEMBL15433994 0.85 FGFR4 (1.00) FGFR4FGFR2FGFR1FGFR3
SCHEMBL19507767 0.85 FGFR4 (0.73) FGFR4FGFR2FGFR1FGFR3
SCHEMBL16071655 0.84 FGFR1 (0.81) FGFR4FGFR2FGFR1EGFRFGFR3
SCHEMBL24690432 0.82 FGFR4 (0.69) FGFR4FGFR2FGFR1MAPK3FGFR3
SCHEMBL16072052 0.81 FGFR4 (0.69) FGFR4FGFR2FGFR1MAPK3FGFR3
SCHEMBL18895840 0.81 FGFR1 (0.82) FGFR4FGFR2FGFR1EGFRFGFR3
SCHEMBL16071658 0.80 FGFR1 (0.74) FGFR4FGFR2FGFR1EGFRFGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10196436-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2019-02-05 — — US disclosed
US-20170066812-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2017-03-09 — — US disclosed
US-20170066812-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2017-03-09 — — US disclosed
US-9340514-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2016-05-17 — — US disclosed
US-9340514-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2016-05-17 — — US disclosed
US-9126951-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2015-09-08 — — US disclosed
US-9126951-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2015-09-08 — — US disclosed
US-20150210694-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2015-07-30 — — US disclosed
US-20150210694-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2015-07-30 — — US disclosed
US-20140378481-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2014-12-25 — — US disclosed
US-20140378481-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2014-12-25 — — US disclosed
US-8802697-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2014-08-12 — — US disclosed
US-8802697-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2014-08-12 — — US disclosed
US-20140187559-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2014-07-03 — — US disclosed
US-20140187559-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2014-07-03 — — US disclosed
US-20140088100-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES (US) 2014-03-27 — — US disclosed
WO-2014011900-A2 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES (US) 2014-01-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210694-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885FGFR2 2/4885FGFR1 1/4885
US-10196436-B2 Inhibitors of the fibroblast growth factor receptor FGFR1, FGFR2, FGFR3 FGFR4 5/4885FGFR2 2/4885FGFR1 1/4885
US-20140378481-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885FGFR2 2/4885FGFR1 1/4885
US-20140088100-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885FGFR2 2/4885FGFR1 1/4885
US-20170066812-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885FGFR2 2/4885FGFR1 1/4885
US-20140187559-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885FGFR2 2/4885FGFR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback